• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 7, 2023

    3/7/23 8:37:46 AM ET
    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Real Estate
    Finance
    Managed Health Care
    Health Care
    Get the next $AFCG alert in real time by email

    Companies Reporting Before The Bell

    • Cohen & Co (AMEX:COHN) is likely to report earnings for its fourth quarter.

    • Xtant Medical Holdings (AMEX:XTNT) is expected to report earnings for its fourth quarter.

    • Ferguson (NYSE:FERG) is likely to report quarterly earnings at $2.01 per share on revenue of $6.84 billion.

    • Zevra Therapeutics (NASDAQ:ZVRA) is likely to report quarterly loss at $0.17 per share on revenue of $3.20 million.

    • Westwater Resources (AMEX:WWR) is estimated to report earnings for its fourth quarter.

    • Voyager Therapeutics (NASDAQ:VYGR) is estimated to report quarterly loss at $0.55 per share on revenue of $4.19 million.

    • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly loss at $0.46 per share on revenue of $6.00 million.

    • Alaunos Therapeutics (NASDAQ:TCRT) is likely to report earnings for its fourth quarter.

    • Dole (NYSE:DOLE) is expected to report quarterly earnings at $0.05 per share on revenue of $2.26 billion.

    • OptiNose (NASDAQ:OPTN) is likely to report quarterly loss at $0.17 per share on revenue of $20.69 million.

    • CorEnergy Infr Trust (NYSE:CORR) is projected to report earnings for its fourth quarter.

    • AFC Gamma (NASDAQ:AFCG) is expected to report quarterly earnings at $0.58 per share on revenue of $18.37 million.

    • Vivid Seats (NASDAQ:SEAT) is expected to report quarterly earnings at $0.12 per share on revenue of $154.51 million.

    • Tremor Intl (NASDAQ:TRMR) is projected to report quarterly earnings at $0.37 per share on revenue of $103.13 million.

    • Thor Industries (NYSE:THO) is projected to report quarterly earnings at $1.13 per share on revenue of $2.49 billion.

    • Sophia Genetics (NASDAQ:SOPH) is likely to report earnings for its fourth quarter.

    • Canaan (NASDAQ:CAN) is expected to report quarterly loss at $0.17 per share on revenue of $43.59 million.

    • Enfusion (NYSE:ENFN) is expected to report quarterly earnings at $0.03 per share on revenue of $40.00 million.

    • Ranger Energy Services (NYSE:RNGR) is likely to report quarterly earnings at $0.36 per share on revenue of $171.20 million.

    • Neuronetics (NASDAQ:STIM) is projected to report quarterly loss at $0.38 per share on revenue of $16.82 million.

    • Dick's Sporting Goods (NYSE:DKS) is likely to report quarterly earnings at $2.87 per share on revenue of $2.

    • 908 Devices (NASDAQ:MASS) is expected to report quarterly loss at $0.26 per share on revenue of $11.43 million.

    • Autolus Therapeutics (NASDAQ:AUTL) is projected to report quarterly loss at $0.27 per share on revenue of $3.20 million.

    • Latham Group (NASDAQ:SWIM) is projected to report quarterly loss at $0.07 per share on revenue of $101.66 million.

    • Landsea Homes (NASDAQ:LSEA) is likely to report quarterly earnings at $0.75 per share on revenue of $441.48 million.

    • Verona Pharma (NASDAQ:VRNA) is estimated to report quarterly loss at $0.10 per share on revenue of $3.57 million.

    • First Watch Restaurant Gr (NASDAQ:FWRG) is likely to report quarterly earnings at $0.02 per share on revenue of $187.25 million.

    • Squarespace (NYSE:SQSP) is estimated to report quarterly earnings at $0.11 per share on revenue of $222.11 million.

    • Sea (NYSE:SE) is estimated to report quarterly loss at $0.77 per share on revenue of $3.12 billion.

    • BlackSky Technology (NYSE:BKSY) is likely to report quarterly loss at $0.16 per share on revenue of $19.62 million.

    • Perfect (NYSE:PERF) is projected to report quarterly earnings at $0.02 per share on revenue of $15.34 million.

    • Wag Group (NASDAQ:PET) is expected to report earnings for its fourth quarter.

    • ESAB (NYSE:ESAB) is expected to report quarterly earnings at $0.88 per share on revenue of $586.25 million.

    Companies Reporting After The Bell

    • Cumberland (NASDAQ:CPIX) is estimated to report earnings for its fourth quarter.

    • Red Cat Holdings (NASDAQ:RCAT) is expected to report quarterly loss at $0.09 per share on revenue of $2.65 million.

    • Momentus (NASDAQ:MNTS) is expected to report quarterly loss at $0.28 per share on revenue of $500 thousand.

    • Cherry Hill Mortgage (NYSE:CHMI) is projected to report quarterly earnings at $0.27 per share on revenue of $5.10 million.

    • Full House Resorts (NASDAQ:FLL) is likely to report quarterly loss at $0.11 per share on revenue of $39.53 million.

    • CPS Technologies (NASDAQ:CPSH) is projected to report earnings for its fourth quarter.

    • W&T Offshore (NYSE:WTI) is estimated to report quarterly earnings at $0.06 per share on revenue of $182.38 million.

    • Rigel Pharmaceuticals (NASDAQ:RIGL) is expected to report quarterly loss at $0.11 per share on revenue of $27.97 million.

    • Durect (NASDAQ:DRRX) is expected to report quarterly loss at $0.55 per share on revenue of $3.48 million.

    • Intellicheck (NASDAQ:IDN) is likely to report quarterly loss at $0.03 per share on revenue of $4.60 million.

    • Fuel Tech (NASDAQ:FTEK) is projected to report quarterly loss at $0.03 per share on revenue of $6.38 million.

    • Treace Medical Concepts (NASDAQ:TMCI) is estimated to report quarterly loss at $0.14 per share on revenue of $44.40 million.

    • Invesco National AMT-Free Municipal Bond ETFo (NYSE:PZA) is estimated to report earnings for its fourth quarter.

    • VanEck Energy Income ETF (NYSE:EINC) is projected to report earnings for its fourth quarter.

    • Maxeon Solar Technologies (NASDAQ:MAXN) is likely to report earnings for its fourth quarter.

    • TDCX (NYSE:TDCX) is projected to report quarterly earnings at $0.14 per share on revenue of $135.63 million.

    • Aquestive Therapeutics (NASDAQ:AQST) is likely to report quarterly loss at $0.23 per share on revenue of $10.42 million.

    • Couchbase (NASDAQ:BASE) is expected to report quarterly loss at $0.34 per share on revenue of $38.26 million.

    • CarParts.com (NASDAQ:PRTS) is expected to report quarterly loss at $0.11 per share on revenue of $151.18 million.

    • Marinus Pharma (NASDAQ:MRNS) is expected to report quarterly loss at $0.70 per share on revenue of $5.27 million.

    • Arlo Technologies (NYSE:ARLO) is expected to report quarterly loss at $0.10 per share on revenue of $107.44 million.

    • Forian (NASDAQ:FORA) is expected to report quarterly loss at $0.27 per share on revenue of $27.00 million.

    • Ero Copper (NYSE:ERO) is likely to report quarterly earnings at $0.40 per share on revenue of $154.69 million.

    • Allied Motion (NASDAQ:AMOT) is estimated to report quarterly earnings at $0.50 per share on revenue of $126.17 million.

    • Yext (NYSE:YEXT) is likely to report quarterly earnings at $0.03 per share on revenue of $100.39 million.

    • Synchronoss Technologies (NASDAQ:SNCR) is expected to report quarterly earnings at $0.06 per share on revenue of $65.23 million.

    • Invesco DWA Industrials Momentum ETF (NASDAQ:PRN) is projected to report quarterly loss at $0.50 per share on revenue of $3.97 million.

    • Profound Medical (NASDAQ:PROF) is estimated to report quarterly loss at $0.36 per share on revenue of $2.72 million.

    • Agiliti (NYSE:AGTI) is estimated to report quarterly earnings at $0.17 per share on revenue of $272.74 million.

    • Cricut (NASDAQ:CRCT) is projected to report quarterly earnings at $0.06 per share on revenue of $241.40 million.

    • CrowdStrike Holdings (NASDAQ:CRWD) is expected to report quarterly earnings at $0.43 per share on revenue of $624.95 million.

    • Accelerate Diagnostics (NASDAQ:AXDX) is likely to report quarterly loss at $0.15 per share on revenue of $2.87 million.

    • Crescent Energy (NYSE:CRGY) is estimated to report quarterly earnings at $0.74 per share on revenue of $617.40 million.

    • SoundHound AI (NASDAQ:SOUN) is estimated to report quarterly loss at $0.17 per share on revenue of $8.74 million.

    • BSQUARE (NASDAQ:BSQR) is projected to report earnings for its fourth quarter.

    • PCTEL (NASDAQ:PCTI) is expected to report quarterly earnings at $0.16 per share on revenue of $26.00 million.

    • Stitch Fix (NASDAQ:SFIX) is likely to report quarterly loss at $0.32 per share on revenue of $393.57 million.

    • Harte-Hanks (NASDAQ:HHS) is projected to report quarterly earnings at $0.10 per share on revenue of $52.20 million.

    • Zymeworks (NASDAQ:ZYME) is estimated to report quarterly earnings at $3.12 per share on revenue of $214.33 million.

    • MasterBrand (NYSE:MBC) is projected to report quarterly earnings at $0.51 per share on revenue of $769.00 million.

    • Casey's General Stores (NASDAQ:CASY) is projected to report quarterly earnings at $1.60 per share on revenue of $3.59 billion.

    • Energy Vault Holdings (NYSE:NRGV) is projected to report quarterly loss at $0.15 per share on revenue of $65.45 million.

    • Akili (NASDAQ:AKLI) is likely to report quarterly loss at $0.30 per share on revenue of $80 thousand.

    • Weyco Group (NASDAQ:WEYS) is expected to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFCG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFCG
    $AGTI
    $AKLI
    $AMOT

    CompanyDatePrice TargetRatingAnalyst
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    CrowdStrike Holdings Inc.
    $CRWD
    2/13/2026$446.00Hold → Buy
    HSBC Securities
    Ero Copper Corp.
    $ERO
    2/9/2026Buy → Neutral
    BofA Securities
    Casey's General Stores Inc.
    $CASY
    1/21/2026Buy → Neutral
    Northcoast
    Casey's General Stores Inc.
    $CASY
    1/20/2026$730.00Outperform
    BNP Paribas Exane
    Ero Copper Corp.
    $ERO
    1/14/2026Hold → Buy
    Canaccord Genuity
    Thor Industries Inc.
    $THO
    1/13/2026$133.00Hold → Buy
    Loop Capital
    CrowdStrike Holdings Inc.
    $CRWD
    1/12/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO and CS Macan William Andrew sold $4,626 worth of shares (3,427 units at $1.35), decreasing direct ownership by 0.39% to 880,134 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    2/27/26 4:34:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    President and CEO Sullivan Keith J sold $11,410 worth of shares (8,452 units at $1.35), decreasing direct ownership by 0.55% to 1,524,713 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    2/27/26 4:33:47 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Piconi Robert bought $24,412 worth of shares (7,500 units at $3.25), increasing direct ownership by 0.04% to 20,090,637 units (SEC Form 4)

    4 - Energy Vault Holdings, Inc. (0001828536) (Issuer)

    2/26/26 1:47:43 PM ET
    $NRGV
    Industrial Machinery/Components
    Miscellaneous

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Piconi Robert bought $24,412 worth of shares (7,500 units at $3.25), increasing direct ownership by 0.04% to 20,090,637 units (SEC Form 4)

    4 - Energy Vault Holdings, Inc. (0001828536) (Issuer)

    2/26/26 1:47:43 PM ET
    $NRGV
    Industrial Machinery/Components
    Miscellaneous

    Director Castanon Moats Maria bought $166,398 worth of shares (300 units at $554.66), increasing direct ownership by 60% to 803 units (SEC Form 4)

    4 - CASEYS GENERAL STORES INC (0000726958) (Issuer)

    1/6/26 2:20:38 PM ET
    $CASY
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Director Tannenbaum Leonard M bought $76,250 worth of shares (25,000 units at $3.05), increasing direct ownership by 0.43% to 5,861,098 units (SEC Form 4)

    4 - Advanced Flower Capital Inc. (0001822523) (Issuer)

    12/15/25 4:29:58 PM ET
    $AFCG
    Real Estate
    Finance

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CrowdStrike upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded CrowdStrike from Hold to Buy and set a new price target of $446.00

    2/13/26 8:22:01 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Ero Copper downgraded by BofA Securities

    BofA Securities downgraded Ero Copper from Buy to Neutral

    2/9/26 7:00:02 AM ET
    $ERO
    Metal Mining
    Basic Materials

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    SEC Filings

    View All

    Energy Vault Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Energy Vault Holdings, Inc. (0001828536) (Filer)

    2/27/26 4:44:46 PM ET
    $NRGV
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 10-K filed by Treace Medical Concepts Inc.

    10-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    2/27/26 7:14:20 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    2/27/26 7:10:38 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    W&T Offshore Announces Timing of Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE:WTI) (the "Company") today announced the timing of its fourth quarter and full year 2025 earnings release and conference call. The Company said it will issue its fourth quarter and full year 2025 earnings release on Thursday, March 5, 2026, after the close of trading on the NYSE and host a conference call to discuss financial and operational results on Friday, March 6, 2026, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time). Interested parties may participate by dialing (844) 739-3797. International parties may dial (412) 317-5713. Participants should request to be joined to the "W&T Offshore, Inc. Conference Call." Th

    2/27/26 1:30:00 PM ET
    $WTI
    Oil & Gas Production
    Energy

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    ESAB Corporation Board Declares Dividend

    ESAB Corporation ("ESAB" or the "Company") (NYSE:ESAB), a focused premier industrial compounder, announced today that its Board of Directors has declared a quarterly cash dividend of $0.10 per share of the Company's common stock. The dividend is payable on April 17, 2026 to shareholders of record as of April 2, 2026. About ESAB Corporation Founded in 1904, ESAB Corporation (NYSE:ESAB) is a focused premier industrial compounder. The Company's rich history of innovative products, workflow solutions and business system ESAB Business Excellence, enables the Company's purpose of Shaping the world we imagineTM. ESAB Corporation is based in North Bethesda, Maryland and employs approximately 10

    2/26/26 4:30:00 PM ET
    $ESAB
    Industrial Machinery/Components
    Industrials

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Leadership Updates

    Live Leadership Updates

    View All

    Cohen & Company Announces Appointment of Pawel Skonieczka as Managing Director to Lead Coverage of Space Technology, Aerospace, & Communications Infrastructure in Capital Markets Segment

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- After nearly doubling deal flow and closing $43 billion in transactions in 2025, Cohen & Company Capital Markets ("CCM"), a division of Cohen & Company Securities, LLC, an indirect, controlled subsidiary of Cohen & Company Inc. (NYSE:COHN), announced the appointment of Pawel Skonieczka as a Managing Director to lead the expansion of the firm's advisory capabilities across Space Technology, Aerospace, and Communications Infrastructure. Mr. Skonieczka brings nearly two decades of experience advising public and private companies, financial sp

    2/26/26 10:43:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

    SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). "As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "We are thrilled to welcome Mr. Clifton as Chief Financial Officer. He brings extensive public company, global finance, and operations leadership

    2/24/26 3:42:26 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Financials

    Live finance-specific insights

    View All

    W&T Offshore Announces Timing of Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE:WTI) (the "Company") today announced the timing of its fourth quarter and full year 2025 earnings release and conference call. The Company said it will issue its fourth quarter and full year 2025 earnings release on Thursday, March 5, 2026, after the close of trading on the NYSE and host a conference call to discuss financial and operational results on Friday, March 6, 2026, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time). Interested parties may participate by dialing (844) 739-3797. International parties may dial (412) 317-5713. Participants should request to be joined to the "W&T Offshore, Inc. Conference Call." Th

    2/27/26 1:30:00 PM ET
    $WTI
    Oil & Gas Production
    Energy

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    ESAB Corporation Board Declares Dividend

    ESAB Corporation ("ESAB" or the "Company") (NYSE:ESAB), a focused premier industrial compounder, announced today that its Board of Directors has declared a quarterly cash dividend of $0.10 per share of the Company's common stock. The dividend is payable on April 17, 2026 to shareholders of record as of April 2, 2026. About ESAB Corporation Founded in 1904, ESAB Corporation (NYSE:ESAB) is a focused premier industrial compounder. The Company's rich history of innovative products, workflow solutions and business system ESAB Business Excellence, enables the Company's purpose of Shaping the world we imagineTM. ESAB Corporation is based in North Bethesda, Maryland and employs approximately 10

    2/26/26 4:30:00 PM ET
    $ESAB
    Industrial Machinery/Components
    Industrials

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Landsea Homes Corporation

    SC 13G - Landsea Homes Corp (0001721386) (Subject)

    12/13/24 8:08:18 PM ET
    $LSEA
    Homebuilding
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Ranger Energy Services Inc.

    SC 13D/A - Ranger Energy Services, Inc. (0001699039) (Subject)

    12/12/24 6:49:54 PM ET
    $RNGR
    Oilfield Services/Equipment
    Energy